IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
If you’re looking to outsource drug product development to a CDMO, you need a collaborative partner who will engage you deeply to understand the unique needs of your project.
From pre-formulation to commercial manufacturing and packaging, you can trust Cambrex to deliver your complex dosage forms with the perfect combination of technology, expertise, and collaboration.
We are equipped to take on projects at any size or scale, offering established pediatric formulation and development expertise and to-scale manufacturing capabilities.
Biopharma companies at all stages of development, rely on our expertise and broad capabilities to produce the clinical trial supply of drug products they need, when they need them.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
01.10.2011
East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, “Cambrex”) will be exhibiting its small molecule API products, services and technologies designed to enhance the efficacy of finished drug products at InformexUSA 2011, February 7-10 in Charlotte, NC. In addition, Cambrex personnel will give two presentations at the Informex Showcases on February 7.
Cambrex will be showcasing its contract service capabilities ranging from development to finished dosage form manufacture with a portfolio of offerings that include controlled substances, high potency APIs, high energy chemistries, drug delivery and enzymatic biotransformation technologies. Cambrex manufactures over 120 generic and branded APIs, along with advanced intermediate products.
During the Informex Exhibitor Showcase, Dan Giambattisto, Vice President of Drug Delivery will present the latest developments in Cambrex’s drug delivery and final dosage formulation and manufacturing capabilities. Cambrex has proprietary platforms designed to deliver technology-enhanced APIs and novel dosage forms that accelerate the commercialization of finished drug products. In addition, Mr. Giambattisto will discuss the recent acquisition of Cambrex Zenara which has furthered Cambrex’s leadership in Nicotine Replacement Therapy products.
Dr. Antje Gupta, General Manager of Cambrex IEP, will present at the Informex Technology Showcase. Her presentation will detail Cambrex’s enzymatic enantioselective reduction and transaminase technologies, and the benefits of using this green technology for cost-effective production of chirally pure intermediates and APIs.
Cambrex is exhibiting at booth 1223 in the Charlotte Convention Center during InformexUSA. (NYSE: CBM, “Cambrex”) will be exhibiting its small molecule API products, services and technologies designed to enhance the efficacy of finished drug products at InformexUSA 2011, February 7-10 in Charlotte, NC. In addition, Cambrex personnel will give two presentations at the Informex Showcases on February 7.
Cambrex is exhibiting at booth 1223 in the Charlotte Convention Center during InformexUSA.